Potential pathway to improved stroke recovery

Researchers from Osaka University, Japan provide new hope for patients who experience ischemic strokes. They have identified two proteins, R-spondin 3 (RSPO3) and LGR4, that trigger a cascade of reactions in cells (signalling pathways) to reduce inflammation in the ischemic brain. RSPO3 and LGR4 also stimulate the growth of extensions from neurons, a process called neurite outgrowth.

Ischemic stroke, caused by a blockage of blood flow to the brain, is a common cause of death and disability. Treatments are urgently needed to improve patient outcomes, because recovery currently depends largely on the timely injection of a blood clot-dissolving drug. Priorities for therapy include limiting inflammation at the ischemic site and rebuilding neuronal connections damaged by the stroke. However, a molecule that can achieve these therapeutic effects has remained elusive. The findings concerning the two proteins: RSPO3 and LGR4 ,were published in Stroke.

“Previous studies showed that RSPO3 was beneficial in lung injuries caused by inflammation. We also knew that RSPO3 stimulates a signalling pathway, named the ‘canonical Wnt pathway’, that promotes neurite outgrowth,” explained Munehisa Shimamura, lead author of the study. “We wondered whether RSPO3 reduces inflammation and promotes neurite outgrowth after ischemic stroke.”

RSPO3 and LGR4 are present in the same brain structures, and that RSPO3 activates LGR4 to stimulate the canonical Wnt pathway. The team from Osaka University localised RSPO3 in endothelial cells and LGR4 in microglia/macrophage cells and neurons in the ischemic brain.

“Because of this close localisation, RSPO3 could act on LGR4,” added Hironori Nakagami, a senior author of the study. “To test this hypothesis, we injected RSPO3 into the brains of mice 24 and 48 hours after ischemic stroke.”

Administered RSPO3 and RSPO3 secreted by endothelial cells promote neurite outgrowth and neuroprotection by suppressing TLR2, TLR4, and TLR9-induced inflammation in microglia and by acting directly on neurons (A). RSPO3 stimulates nuclear translocation of β-catenin, resulting in the downregulation of TLR4 expression and promotion of neurite outgrowth (B). (Credit: Stroke in Press)

Remarkably, nine days after the stroke, mice that were injected with RSPO3 exhibited fewer sensory and motor deficits than mice injected with a control protein. The expression of pro-inflammatory factors was reduced, whereas signs of neurite outgrowth increased. It was found that RSPO3/LGR4 decreased the expression of TLR4, which is one of proteins essential for inducing inflammation.

These findings are particularly exciting because RPSO3 was given to mice one day after the stroke, suggesting a potential benefit to treatments in later stages of stroke. Thus, targeting RSPO3/LGR4 signalling is a promising lead for developing new therapies for ischemic stroke and improving patient outcomes.